Human rights and access to hepatitis C treatment for people who inject drugs

International Journal of Drug Policy

Volumn 26, Issue 11, 2015, Pages 1072-1080

  Wolfe, D ^a   Luhmann, N ^b   Harris, M ^c   Momenghalibaf, A ^a   Albers, E ^d   Byrne, J ^e   Swan, T ^f  

^a OPEN SOCIETY FOUNDATIONS   (United States)

^b République Démocratique du Congo   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Unit 2C05   (United Kingdom)

^e Australian Injecting and Illicit Drug Users League (AIVL)   (Australia)

^f Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CORRELATION ANALYSIS; DETENTION; DRUG COST; DRUG USE; FEE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN RIGHTS; HUMAN RIGHTS ABUSE; NAMED GROUPS OF PERSONS; NOTE; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; PRISON; REGISTRATION; REHABILITATION CENTER; SOCIAL STIGMA; COMPLICATION; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE DELIVERY; REHABILITATION; SUBSTANCE ABUSE;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMAN RIGHTS; HUMANS; SOCIAL STIGMA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84942191630     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.05.007     Document Type: Note

References (80)

1. All-Party Parliamentary Hepatology Group In the dark: An audit of hospital hepatitis C services across England 2010, All-Party Parliamentary Hepatology Group, London.
2. Alliance Ukraine News: Hepatitis C 2014, Retrieved from http://www.aidsalliance.org.ua/cgi-bin/index.cgi?url=/en/news/index.htm (12.12.14).
3. Amon J.J., Pearshouse R., Cohen J.E., Schleifer R. Compulsory drug detention in East and Southeast Asia: Evolving government, UN and donor responses. International Journal of Drug Policy 2014, 25(1):13-20. 10.1016/j.drugpo.2013.05.019.
4. ANPUD Barriers to hepatitis C diagnosis, management and treatment among people who inject drugs in 4 Asian countries 2011, Asian Network of People who Use Drugs, Bangkok.
5. Aspinall E.J., Corson S., Doyle J.S., Grebely J., Hutchinson S.J., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(Suppl. 2):S80-S89. 10.1093/cid/cit306.
6. Attaran A. Adherence to HAART: Africans take medicines more faithfully than North Americans. PLoS Medicine 2007, 4(2):e83.
7. Australian Injecting and Illicit Drug Users League Decision not to recommend ground-breaking new treatment for hepatitis C short-sighted and unacceptable 2014, (Press Release). Retrieved from http://www.aivl.org.au/media_release/decision-not-to-recommend-ground-breaking-new-treatment-for-hepatitic-c-short-sighted-unacceptable/ (05.12.14).
8. Bivol S., Sarang A. Hepatitis C in Russia: An epidemic of negligence 2014, Andre Rylkov Foundation for Health and Social Justice, Moscow.
9. Bobrova N., Rhodes T., Power R., Alcorn R., Neifeld E., Krasiukov N., et al. Barriers to accessing drug treatment in Russia: A qualitative study among injecting drug users in two cities. Drug and Alcohol Dependence 2006, 82(Suppl. 1):S57-S63.
10. Bouscaillou J., Champagnat J., Luhmann N., Avril E., Inaridze I., Miollany V., et al. Hepatitis C among people who inject drugs in Tbilisi, Georgia: An urgent need for prevention and treatment. International Journal of Drug Policy 2014, 25(5):871-878.
11. Bruggmann P., Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015, 26(Suppl. 1):S22-S26.
12. Burris S., Blankenship K.M., Donoghoe M., Sherman S., Vernick J.S., Case P., et al. Addressing the "risk environment" for injection drug users: The mysterious case of the missing cop. Milbank Quarterly 2004, 82(1):125-156.
13. Cai Wei Ping Pegylated interferon - Practice and policy. Red Ribbon Forum 2014.
14. Chak E., Talal A.H., Sherman K.E., Schiff E.R., Saab S. Hepatitis C virus infection in USA: An estimate of true prevalence. Liver International 2011, 31(8):1090-1101. 10.1111/j.1478-3231.2011.02494.x.
15. Committee on Economic Social and Cultural Rights General Comment No. 14: The Right to the Highest Attainable Standard of Health, UN Doc. No. E/C.12/2000/4 2000, Retrieved from http://www.unhcr.org/refworld/pdfid/4538838d0.pdf (07.12.14).
16. Csete J., Wolfe D. Viral transmission linked to injecting illicit drugs: Finding the best medicine. Future Virology 2013, 8(2):105-107.
17. Davis S.L. Human rights and the global fund to fight AIDS, tuberculosis, and malaria. Health and Human Rights 2014, 16(1):134-147.
18. Donnelly J. Universal human rights in theory and practice 2013, Cornell University Press.
19. ECHR Chamber judgment: Poghosyan v. georgia 2009, Retrieved from http://hudoc.echr.coe.int/sites/eng/pages/search.aspx?i=003-2643820-2890164 (04.01.15).
20. Elovich R., Drucker E. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduction Journal 2008, 5(1):23.
21. Enfermos de hepatitis C se encierran para reclamar los nuevos fármacos. (2014, 18 December). El Pais. Retrieved from (18.12.14). http://politica.elpais.com/politica/2014/12/18/actualidad/1418902901_615124.html.
22. European Monitoring Centre for Drugs and Drug Addiction Country overview: Georgia 2014, Retrieved from http://www.emcdda.europa.eu/publications/country-overviews/ge (15.12.14).
23. Frank C., Mohamed M.K., Strickland G.T., Lavanchy D., Arthur R.R., Magder L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891. 10.1016/S0140-6736(99)06527-7.
24. Fraser S., Moore D. Harm reduction and hepatitis C: On the ethics and politics of prevention and treatment. Addiction Research & Theory 2011, 19(4):375-379.
25. Fraser S., Moore D., Keane H. Habits: Remaking addiction 2014, Palgrave Macmillan.
26. Friedman S.R., de Jong W., Rossi D., Touze G., Rockwell R., Des Jarlais D.C., et al. Harm reduction theory: Users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups. International Journal of Drug Policy 2007, 18(2):107-117. 10.1016/j.drugpo.2006.11.006.
27. Gilead Sciences Gilead announces generic licensing agreements to increase access to hepatitis C treatments in developing countries 2014, (Press Release). Retrieved from http://www.gilead.com/news/press-releases/2014/9/gilead-announces-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments-in-developing-countries (20.12.14).
28. Global Commission on Drug Policy The negative impact of the war on drugs on public health: The hidden hepatitis C epidemic 2013, Global Commission on Drug Policy, Sao Paolo.
29. Global Fund to Fight AIDS TB and Malaria Global Fund Financing of Hepatitis C Treatment. GF/B32/DPO7 2014, Retrieved from http://www.theglobalfund.org/Knowledge/Decisions/GF/B32/DP07/ (27.12.14).
30. Grady B.P., Schinkel J., Thomas X.V., Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clinical Infectious Diseases 2013, 57(Suppl. 2):S105-S110. 10.1093/cid/cit301.
31. Grebely J., Dore G.J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31(4):331-339. 10.1055/s-0031-1297922.
32. Grebely J., Dore G.J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72.
33. Grebely J., Oser M., Taylor L.E., Dore G.J. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. Journal of Infectious Diseases 2013, 207(Suppl. 1):S19-S25. 10.1093/infdis/jis928.
34. Grebely J., Tyndall M.W. Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV and AIDS 2011, 6(6):501-507. 10.1097/COH.0b013e32834bcb36.
35. Gruskin S., Mills E.J., Tarantola D. History, principles, and practice of health and human rights. Lancet 2007, 370(9585):449-455. 10.1016/S0140-6736(07)61200-8.
36. Harris M., et al. Treatment as prevention and PWID. Int J Drug Policy 2015, 26(10):963-969.
37. Harris M., Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal 2013, 10:7. 10.1186/1477-7517-10-7.
38. Harris M., Rhodes T., Martin A. Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. Social Science and Medicine 2013, 83:19-26. 10.1016/j.socscimed.2013.01.031.
39. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
40. Hutchinson S.J. Translating research into public health policy: Scotland's Action Plan on Hepatitis C 2013, September, Paper presented at the International Network on Hepatitis Among Substance Users Conference, Munich.
41. Infectious Diseases Society of America, & HIV Medicine Association IDSA, HIVMA call for state medicaid programs to lift hepatitis C prescribing restrictions from ID and HIV doctors 2014, (Press Release). Retrieved from http://www.idsociety.org/HCV_Provider_Restrictions/ (09.09.14).
42. Karnish C. The risky business of limiting medicaid access to Sovaldi 2014, Governing, Retrieved from http://www.governing.com/topics/health-human-services/gov-hepatitis-coverage-solvaldi-lawsuits.html (10.12.14).
43. Kirtadze I., Otiashvili D., O'Grady K.E., Zule W., Krupitsky E., Wechsberg W.M., et al. Twice stigmatized: Provider's perspectives on drug-using women in the Republic of Georgia. Journal of Psychoactive Drugs 2013, 45(1):1-9. 10.1080/02791072.2013.763554.
44. Knopf A. OTP patients, ideal for new hepatitis C treatment, put on bottom of list by payers. Alcoholism and drug addiction weekly 2014, Retrieved from http://www.alcoholismdrugabuseweekly.com/Article-Detail/otp-patients-ideal-for-new-hepatitis-c-medication-put-on-bottom-of-list-by-payers.aspx (27.12.14).
45. LBHM Empowering drug users: Strengthening drug user paralegals' capacity in documentation and advocacy 2011, LBH Masyarakat, Jakarta, Indonesia.
46. Martin J.P. 25+ human rights documents 2001, Columbia University Center for the Study of Human Rights, New York.
47. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 2010, 375(9719):1014-1028.
48. Meier B.M., Yamin A.E. Right to health litigation and HIV/AIDS policy. Journal of Law, Medicine & Ethics 2011, 39(s1):81-84.
49. Ministry of Corrections and Legal Assistance of Georgia Statistics: Amnesty 2014, Retrieved from http://www.mcla.gov.ge/index.php?action=page&p_id=998&lang=eng (27.12.14).
50. Momenghalibaf A. Hepatitis C treatment: Price, profits, and barriers to access 2014, Open Society Foundations, New York.
51. Moon S. Respecting the right to access to medicines: Implications of the UN Guiding Principles on Business and Human Rights for the pharmaceutical industry. Health and Human Rights 2013, 15(1):32-43.
52. MSF Barriers to access and scale up of Hepatitis C (HCV) treatment-Gilead's Anti-diversion program 2015, Retrieved from http://www.msfaccess.org/content/barriers-access-and-scale-hepatitis-c-hcv-treatment-gileads-anti-diversion-program (05.01.15).
53. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378(9791):571-583. 10.1016/S0140-6736(11)61097-0.
54. OSF Hepatitis C Treatment for People who Inject Drugs: Report from the Bangkok meeting 2015, Open Society Foundations, New York.
55. Palmateer N.E., Taylor A., Goldberg D.J., Munro A., Aitken C., Shepherd S.J., et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLOS ONE 2014, 9(8):e104515. 10.1371/journal.pone.0104515.
56. Parikh N., Nonnemacher M.R., Pirrone V., Block T., Mehta A., Wigdahl B. Substance abuse, HIV-1 and hepatitis. Current HIV Research 2012, 10(7):557-571.
57. PKNI The urgent need for improved hepatitis C prevention, care and treatment for people who inject drugs in Indonesia 2014, Persaudaraan Korban Napza Indonesia, Jakarta.
58. Rahman F., Crofts N. Drug law reform in East and Southeast Asia 2013, Lexington Books, Lanham.
59. Razavi H., Waked I., Sarrazin C., Myers R., Idilman R., Calinas F., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis 2014, 21(s1):34-59.
60. Rhodes T., Harris M., Martin A. Negotiating access to medical treatment and the making of patient citizenship: The case of hepatitis C treatment. Sociology of Health and Illness 2013, 35(7):1023-1044. 10.1111/1467-9566.12018.
61. Room R. Addiction and personal responsibility as solutions to the contradictions of neoliberal consumerism. Critical Public Health 2011, 21(2):141-151.
62. Sabelashvili P. Country perspectives 2014, December 6-8, Paper presented at the Hepatitis C Treatment for People who Inject Drugs, Bangkok.
63. Sanger-Katz M. Why the hepatitis cure Sovaldi is a budgetary disaster for prisons. New York Times 2014, August 7, Retrieved from http://www.nytimes.com/2014/08/07/upshot/why-the-hepatitis-cure-sovaldi-is-a-budgetary-disaster-for-prisons.html?_r=0 (20.12.14).
64. Silverman E. How Illinois allocates $84,000 drug for hepatitis C. Wall Street Journal 2014, August 3, Retrieved from http://online.wsj.com/articles/how-illinois-allocates-84-000-drug-for-hepatitis-c-1407114940?mod=Health_and_Wellness_newsreel_5 (01.12.14).
65. TAG 1st Hepatitis C Virus World Community Advisory Board Report 2014, Treatment Action Group, New York.
66. UNITAID World hepatitis day: Why UNITAID is investing in hepatitis C 2014, (Press Release). Retrieved from http://www.unitaid.eu/en/resources/press-centre/20-news/statements/1376-world-hepatitis-day-why-unitaid-is-investing-in-hepatitis-c (27.12.14).
67. US Department of State Georgia 2012 Human Rights Report 2012, Retrieved from http://www.state.gov/documents/organization/204499.pdf (02.12.14).
68. US House of Representatives, Committee on International Relations The United States' war on AIDS, 107th Congress, 1st session Sess. (Hearing, 7 June 2001) 2001, Government Printing Office, Washington.
69. Varan A.K., Mercer D.W., Stein M.S., Spaulding A.C. Hepatitis C seroprevalence among prison inmates since 2001: Still high but declining. Public Health Reports 2014, 129(2):187-195.
70. Vickerman P., Martin N.K., Roy A., Beattie T., Jarlais D.D., Strathdee S., et al. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence 2013, 132(1-2):172-181. 10.1016/j.drugalcdep.2013.01.020.
71. Walmsley R. World prison population list 2012, 16-21. London International Centre for Prison Studies.
72. Wanis H. Hepatitis C treatment in Egypt: Why cost remains a challenge 2014, Egyptian Initiative for Personal Rights, Cairo.
73. WHO The 3×5 initiative 2005, Retrieved from http://www.who.int/3by5/en/ (01.12.14).
74. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: Access, adherence and structural barriers in Asia and the former Soviet Union. International Journal of Drug Policy 2007, 18(4):246-254.
75. Wolfe D., Carrieri M.P., Shepard D. Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward. Lancet 2010, 376(9738):355-366.
76. Wolfe D., Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: Key principles and research needs. Journal of Acquired Immune Deficiency Syndromes 2010, 55(Suppl. 1):S56-S62. 10.1097/QAI.0b013e3181f9c0de.
77. Wolfe D., Cohen J., Doyle H., Margolin T., Wolfe D. Breaking the Links: Legal and paralegal assistance to reduce health risks of police and pre-trial detention of sex workers and people who use drugs. In Structural Approaches in Public Health 2014, Routledge, New York. R. Parker, M. Sommer (Eds.).
78. World Health Organization Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, World Health Organization, Geneva.
79. World Hepatitis Alliance 2014 resolution on viral hepatitis 2014, Retrieved from http://www.worldhepatitisalliance.org/en/id-2014-resolution.html (03.01.15).
80. Yamin A.E. Not just a tragedy: Access to medications as a right under international law. BU Int'l Law Journal 2003, 21:325.